Eric H. Rubin
Impact in
- Oncology top 0.5%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Toxicology top 0.5%
Papers in
-
- Cancer therapeutics and mechanisms 35
- Ubiquitin and proteasome pathways 9
- Oncology 68
- Cancer Treatment and Pharmacology 20
- Lung Cancer Research Studies 15
- Colorectal Cancer Treatments and Studies 10
- Cancer Immunotherapy and Biomarkers 10
- Co-authors
- Susan Goodin (9 shared papers)Zeshaan A. Rasheed (5 shared papers)Ahamed Saleem (18 shared papers)Leroy F. Liu (5 shared papers)Donald Küfe (12 shared papers)Michael P. Kane (3 shared papers)Dale Purves (2 shared papers)Surender Kharbanda (8 shared papers)
- Journals
- Journal of Clinical Oncology (27 papers)Clinical Cancer Research (13 papers)Journal of Biological Chemistry (7 papers)Journal of Neuroscience (5 papers)Cancer Chemotherapy and Pharmacology (5 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Eric H. Rubin
141 papers receiving 6.3k citations
Eric H. Rubin's Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 2.5k
- Toxicology 234
- Molecular Biology 3.3k
- Cancer Research 543
- Developmental Neuroscience 130
Countries citing papers authored by Eric H. Rubin
This map shows the geographic impact of Eric H. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric H. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric H. Rubin more than expected).
Fields of papers citing papers by Eric H. Rubin
This network shows the impact of papers produced by Eric H. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric H. Rubin. The network helps show where Eric H. Rubin may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric H. Rubin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 143 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 498 |
| 2 | 2004 | 254 | |
| 3 | Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. | 2001 | 185 |
| 4 | 2006 | 161 | |
| 5 | 2004 | 153 | |
| 6 | 2003 | 134 | |
| 7 | 1992 | 132 | |
| 8 | 1985 | 130 | |
| 9 | 2014 | 124 | |
| 10 | 2011 | 124 | |
| 11 | 2003 | 122 | |
| 12 | 2015 | 120 | |
| 13 | 2009 | 117 | |
| 14 | 2011 | 114 | |
| 15 | 1986 | 111 | |
| 16 | 1994 | 109 | |
| 17 | 1996 | 107 | |
| 18 | 2022 | 100 | |
| 19 | 1980 | 97 | |
| 20 | 2006 | 95 |
About Eric H. Rubin
Eric H. Rubin is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Cell Biology, having authored 143 papers that have together received 6.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (35 papers), Cancer Treatment and Pharmacology (20 papers), Cancer Genomics and Diagnostics (15 papers), Lung Cancer Research Studies (15 papers), Colorectal Cancer Treatments and Studies (10 papers), Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Ubiquitin and proteasome pathways (9 papers). The work is most often cited by research in Oncology (2.5k citations), Toxicology (234 citations), Molecular Biology (3.3k citations), Cancer Research (543 citations) and Developmental Neuroscience (130 citations). Eric H. Rubin has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Susan Goodin, Zeshaan A. Rasheed, Ahamed Saleem, Leroy F. Liu, Donald Küfe, Michael P. Kane, Dale Purves, Surender Kharbanda, Ajit Bharti and Philip Grant. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Biological Chemistry, Journal of Neuroscience and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.